Stereotactic Body Radiotherapy Using Cyberknife for Localized Prostate Cancer

Authors Information
Article Notes and Dates
To Cite : Kim H, Phak H, Kim W. Stereotactic Body Radiotherapy Using Cyberknife for Localized Prostate Cancer, Rep Radiother Oncol. 2015 ;2(3):e4671. doi: 10.17795/rro-4671.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA. 2015; 65(1): 5-29[DOI]
  • 2. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013; 8: 118[DOI][PubMed]
  • 3. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013; 8: 58[DOI][PubMed]
  • 4. King CR, Brooks JD, Gill H, Presti JJ. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82(2): 877-82[DOI][PubMed]
  • 5. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012; 118(15): 3681-90[DOI][PubMed]
  • 6. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003; 56(4): 1093-104[PubMed]
  • 7. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999; 43(5): 1095-101[PubMed]
  • 8. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002; 52(1): 6-13[PubMed]
  • 9. Fowler JF. The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol. 2005; 44(3): 265-76[DOI][PubMed]
  • 10. Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS. High-dose-rate prostate brachytherapy: an excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol. 2010; 33(5): 481-8[DOI][PubMed]
  • 11. Park YH, Choi IY, Yoon SC, Jang HS, Moon HW, Hong SH, et al. Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer. Prostate Int. 2015; 3(1): 6-9[DOI][PubMed]
  • 12. Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008; 112(1): 55-60[DOI][PubMed]
  • 13. Patel C, Elshaikh MA, Angermeier K, Ulchaker J, Klein EA, Chehade N, et al. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Urology. 2004; 63(1): 110-3[PubMed]
  • 14. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M3, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9: 42[DOI][PubMed]
  • 15. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006; 64(4): 1140-50[DOI][PubMed]
  • 16. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 78(1): 11-8[DOI][PubMed]
  • 17. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007; 84(2): 114-20[DOI][PubMed]
  • 18. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003; 169(3): 974-9[DOI][PubMed]
  • 19. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011; 81(5): 1286-92[DOI][PubMed]
  • 20. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176(4 Pt 1): 1415-9[DOI][PubMed]
  • 21. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014; 4: 240[DOI][PubMed]
  • 22. Vu CC, Haas JA, Katz AE, Witten MR. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer. Front Oncol. 2014; 4: 8[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiaion Alert via Google Reader

Cited By:

Reports of Radiotherapy and Oncology accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check